Neurizon Commences Initiatives to Lift Clinical Hold
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company is in ongoing communication with the US FDA and has submitted a formal request for advice on necessary pharmacokinetic studies. Neurizon plans to proactively commence these studies to generate additional data, which is expected to take around four months to complete.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4D - Half-year Financial Report - 31 December 2024
- FDA Guidance on NUZ-001 IND Application
- US Patent granted for NUZ-001
- Neurizon updates on NUZ-001 IND Application
- Neurizon Files IND Application to Support HEALEY ALS Trial
Later from Neurizon Therapeutics
- NUZ-001 shows promising respiratory outcome
- NUZ-001 Shows Positive Results in Human 3D Brain Model
- NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
- Last Patient Successfully Completes Treatment in OLE Study
- NUZ-001 Shows Promise in a Model of Huntington's Disease
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics